Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15246408 | 1.00 | TRPV1 (0.47) | TRPV1ALDH1A1KDM4EFNTAFNTB | |
| SCHEMBL15246188 | 0.87 | TRPV1 (0.61) | TRPV1ALDH1A1FNTAFNTBPGGT1B | |
| SCHEMBL15228443 | 0.86 | TRPV1 (0.53) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL15246434 | 0.86 | TRPV1 (0.53) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL5502028 | 0.80 | TRPV1 (0.46) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL10418066 | 0.76 | TRPV1 (0.64) | TRPV1ALDH1A1KDM4E | |
| SCHEMBL10418065 | 0.76 | TRPV1 (0.64) | TRPV1ALDH1A1KDM4E | |
| SCHEMBL8624972 | 0.75 | TRPV1 (0.62) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL8624969 | 0.75 | TRPV1 (0.62) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL11410628 | 0.75 | TRPV1 (0.62) | TRPV1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | TRPV1 1283/4885ALDH1A1 3039/4885KDM4E 3078/4885 |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | TRPV1 1283/4885ALDH1A1 3039/4885KDM4E 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.